Transcriptomic analysis showed that GNG5 mRNA levels were significantly higher in all the five subregions of donors with AD in the H-pathology stage compared with those in the non (N)-, low (L)-, and immediate (I)-pathology stages (Fig. 1F, Table S3). This evidence concerns the gene GNG5 and Alzheimer disease.